Smoking is a real health problem worldwide ([@bibr47-1557988319825754]; [@bibr56-1557988319825754]). Current cigarette smoking and lifetime persistent smoking were associated with an increased risk of all-cause, cardiovascular diseases (CVDs), chronic obstructive pulmonary disease, any cancer, and lung cancer mortality ([@bibr47-1557988319825754]). Another old form of tobacco use, namely narghile use, is regaining popularity ([@bibr48-1557988319825754]; [@bibr55-1557988319825754]). The Eastern Mediterranean region has the highest prevalence of narghile use in the world, especially among young people ([@bibr1-1557988319825754]; [@bibr44-1557988319825754]). In North Africa, narghile use was reported by 3.5% of the general population and the majority of narghile smokers (NSs) were males (82.0%; [@bibr3-1557988319825754]). This rate is probably lower than reality, since only participants aged 40--49 years were included ([@bibr3-1557988319825754]). This smoking habit poses great health threats presently. Faced with the "globalization" of the narghile-use phenomenon, the World Health Organization (WHO) has taken up the case and stressed that "it is not only a health risk, but it is also a gateway to smoking for a number of young people" ([@bibr53-1557988319825754], [@bibr55-1557988319825754]).

Habitually, public opinion, and particularly the medical world, misjudges the harmful effects of narghile use, despite its damaging effects on health ([@bibr4-1557988319825754]; [@bibr7-1557988319825754]; [@bibr9-1557988319825754]; [@bibr11-1557988319825754], [@bibr12-1557988319825754], [@bibr13-1557988319825754]; [@bibr20-1557988319825754]; [@bibr50-1557988319825754]). Up-to-date evidence indicates that narghile use is associated with several adverse health effects including cardiorespiratory, hematological, and reproductive systems ([@bibr4-1557988319825754]; [@bibr7-1557988319825754]; [@bibr9-1557988319825754]; [@bibr11-1557988319825754], [@bibr12-1557988319825754], [@bibr13-1557988319825754]; [@bibr20-1557988319825754]; [@bibr50-1557988319825754]). An association between narghile use and malignancies, such as lung, oral, and nasopharyngeal cancer, has been suggested ([@bibr7-1557988319825754]; [@bibr9-1557988319825754]; [@bibr20-1557988319825754]; [@bibr31-1557988319825754]; [@bibr50-1557988319825754]). Studies about the effects of narghile use on biochemical data and metabolic profile are scarce ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]). Even in the WHO second edition related to narghile use, no information about its possible effects on smokers' biochemical or metabolic profile was reported ([@bibr55-1557988319825754]). To the best of the authors' knowledge, only six studies evaluated the biochemical data and the metabolic profiles of NSs ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]), with controversial conclusions. First, the two studies aiming at evaluating the occurrence of the metabolic syndrome (MetS) in NSs, reported a big gap concerning its prevalence (33.1% \[[@bibr43-1557988319825754]\] vs. 46.8% \[[@bibr42-1557988319825754]\]). The comparison of its prevalence between NSs and control groups ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]) identified significant differences between NSs and healthy nonsmokers (HNSs; 33.1 vs. 14.8% \[[@bibr43-1557988319825754]\]; 46.8% vs. 38.8% \[[@bibr42-1557988319825754]\]). Second, while some authors reported that NSs and HNSs were matched with fasting blood glycemia (FBG; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]), high- and low- density lipoprotein cholesterol (HDL-C \[[@bibr2-1557988319825754]; [@bibr43-1557988319825754]\] and LDL-C \[[@bibr2-1557988319825754]; [@bibr34-1557988319825754]\]), triglycerides (TG; [@bibr2-1557988319825754]), and total cholesterol (TC; [@bibr34-1557988319825754]), others reported that as compared to the HNSs' group, the NSs' one has compromised FBG ([@bibr43-1557988319825754]), TG ([@bibr34-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]), HDL-C ([@bibr34-1557988319825754]; [@bibr42-1557988319825754]), LDL-C ([@bibr42-1557988319825754]), and TC ([@bibr42-1557988319825754]). Third, while some authors concluded that NSs and cigarette smokers (CSs) were matched with TG ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr42-1557988319825754]), HDL-C ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]), LDL-C ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr42-1557988319825754]), and TC ([@bibr42-1557988319825754]), others reported that as compared to the CSs' group, the NSs' one has compromised FBG ([@bibr42-1557988319825754]), HDL-C ([@bibr42-1557988319825754]), and TC ([@bibr34-1557988319825754]). The divergence in conclusions can be related to some methodological limitations and/or differences which may affect the results. Four examples can be highlighted. First, the lack of sample size calculation ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]) is a statistically central point since determining the finest size for a study guarantees enough power to distinguish statistical significance and is a serious step in the design of a planned research procedure ([@bibr30-1557988319825754]). Second, the inclusion of elderly subjects more than 60 years of age ([@bibr2-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]) may introduce a bias because the prevalence of altered metabolic data (e.g., MetS) increases with age ([@bibr40-1557988319825754]). Third, the lack of information about the different types of the narghile tobacco used ([@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]), makes any comparison difficult, because in the case of *tombak* or *jurak*, in comparison to *tabamel*, the pattern is different ([@bibr6-1557988319825754]). Fourth, different methods of narghile-use quantification (not reported \[[@bibr26-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]\], run/day \[[@bibr2-1557988319825754]\], total duration of smoking \[[@bibr2-1557988319825754]\], narghile/year \[NY; [@bibr34-1557988319825754]\], and quantity in kg of tobacco smoked/year \[[@bibr34-1557988319825754]\]) were applied. Moreover, the levels of exposure to narghile tobacco, mentioned only in two studies, were imprecise (\>five NY \[[@bibr34-1557988319825754]\], 16 ± 12 years \[[@bibr43-1557988319825754]\]). This situation makes the comparison between studies difficult. Therefore, it is clear that narghile-use research still harbors a lot of deficiencies that need to be further investigated.

Ignoring the damaging effects of narghile use on biochemical and metabolic data will certainly lead to a global public health problem ([@bibr6-1557988319825754], [@bibr7-1557988319825754]; [@bibr55-1557988319825754]), which we can now undertake to prevent. Both the 2005 and 2015 WHO advisory notes on narghile use ([@bibr52-1557988319825754], [@bibr55-1557988319825754]) highlighted the above area of deficiency, and among the aspects requiring further research, the epidemiology of narghile-associated disease risk was recommended. Taking into account the aforementioned methodological limitations/differences ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]) and the WHO recommendations ([@bibr52-1557988319825754], [@bibr55-1557988319825754]), this study aimed to compare the biochemical data and the metabolic profile (especially the presence of a MetS) of exclusive NS (ENSs) with apparently HNSs (AHNSs). The null hypothesis was that there is a divergence between their records.

Population and Methods {#section1-1557988319825754}
======================

Study Design {#section2-1557988319825754}
------------

It was a comparative study performed over a period of 3 months (December 2015 to February 2016) with collaboration between the Departments of Endocrinology and Diabetes, and that of Biochemistry (Farhat HACHED University Hospital, Sousse, Tunisia).

This clinical laboratory report was conducted in agreement with the Declaration of Helsinki. The study approval (number: 2207/2015) was obtained from the Farhat HACHED University Hospital's Ethics Committee. Participants were individually informed about the purpose of the study. Written and informed consent was asked from all study participants who received a report of their explorations. In case of biochemical and/or metabolic abnormalities, participants were cared for by the investigator. Participants were not charged any costs for the accomplished tests.

Sample Size {#section3-1557988319825754}
-----------

The null hypothesis ([@bibr30-1557988319825754]) was H~0~: *m*~1~ = *m*~2~ and the alternative one was H~a~: *m*~1~ = *m*~2~ + *d*; where "*d*" was the difference between two means and *n*~1~ and *n*~2~ were the sample size for two groups (ENSs and AHNSs) such *N* = *n*~1~ + *n*~2~. The total sample size was estimated by using the following formula ([@bibr30-1557988319825754]):

$$N = \frac{\left( \begin{array}{l}
{Z_{\alpha/2}\sqrt{2p\left( {1 - p} \right)} +} \\
{Z_{1 - \beta}\sqrt{p1\left( {1 - p_{1}} \right)p_{2}\left( {1 - p_{2}} \right)}} \\
\end{array} \right)2}{\left( {p_{1} - p_{2}} \right)2}$$

-   "*Z*~α/2~" was the normal deviate at a level of significance (=1.96 for 5% level of significance);

-   "*Z*~1−β~" was the normal deviate at 1 − β% power with β% of Type II error (=1.03 at 85% statistical power);

-   "*r*" equal to *n*~1~/*n*~2~, was the ratio of sample size required for two groups (*r* = 1 gives the sample size distribution as 1:1 for the two groups).

-   "*p*~1~" and "*p*~2~" were the proportion of event of interest (e.g., MetS) for two groups, and "*p*" was equal to (*p*~1~ + *p*~2~)/2. "*p*~1~" and "*p*~2~" were extracted from the study of [@bibr43-1557988319825754] where the prevalences of MetS were 33.1% and 14.8%, respectively, in ENSs' and HNSs' groups. The total sample size for the study was 55 participants (27 ENSs and 27 AHNSs).

Study Population {#section4-1557988319825754}
----------------

Participants were selected by convenience sampling applying the following three methods: (a) an informational letter (including the corresponding researcher cell phone number) announcing the need to recruit ENSs was given to the owners of several local cafés which were highly frequented by NSs; (b) acquaintances (usually hospital workers and friends of medical school students) of people involved in this study; and (c) an article announcing the need to recruit participants was posted in a social network service (Facebook pages of the people involved in the study).

Only males aged 25--45 years free from a known history of metabolic and/or CVDs (e.g., diabetes mellitus \[DM\]; dyslipidemia; arterial hypertension; cerebral vascular stroke; myocardial infarction \[MI\]) were included. Cigarette smoking and any specific treatment for lipid abnormality were applied as noninclusion criteria. Missing biochemical data and a high amount of cumulated smoked narghile (e.g., \>100 NY qualified as outliers) were applied as exclusion criteria.

According to the smoking status, two groups of participants were identified: ENSs' group of more than five NY and AHNSs' group. ENSs were instructed not to smoke during the overnight fasting period and before taking the clinical exam and laboratory tests ([@bibr2-1557988319825754]; [@bibr18-1557988319825754]).

Medical Questionnaire {#section5-1557988319825754}
---------------------

A nonstandardized medical questionnaire was used to assess several participants' characteristics: family and personal medical history (DM, arterial hypertension, cerebral vascular stroke, MI, dyslipidemia, thyroid dysfunction); and personal surgical history (e.g., abdominal-pelvic, urologic, orthopedic, neurological); socioeconomic and schooling levels; and smoking (quantity of used narghile and narghile tobacco type) and alcohol habits.

Two schooling levels were defined: low (illiterate, primary education) and high (secondary and university education; [@bibr8-1557988319825754]). Two socioeconomic levels were defined according to the occupational status: low (e.g., unskilled worker, jobless) and high (e.g., skilled worker, farmer, manager; [@bibr37-1557988319825754]). Students were classified according to their parents' occupational status. Narghile use and type of narghile tobacco used were self-reported. The narghile-use history was defined as NY (number of narghile smoked a day × total number of smoking years; [@bibr6-1557988319825754]). Three types of used narghile tobacco were evaluated: *moassel* (*tabamel*), *tombak*, and/or *jurak* ([@bibr6-1557988319825754]). Alcohol habit was evaluated and two groups of participants were arbitrarily defined: alcohol and nonalcohol consumers.

Anthropometric Data {#section6-1557988319825754}
-------------------

Age (Yr) was noted. Height (±0.01 m) was measured with a height gauge shoes removed, heels joined, and back straight. Weight (±1 kg) was measured with a mechanical scale (*Seca Deutschland*) and the body mass index (BMI, kg/m^2^) was calculated. Waist circumference (WC, cm) was measured with a tape measure midway between the lower rib margin and the iliac crest ([@bibr10-1557988319825754]).

Physical Examination {#section7-1557988319825754}
--------------------

Systolic and diastolic blood pressures (SBP and DBP) were measured using a manual monitor (*Spengler Vaquez-Laubry, France*) with participants seated for at least 5 min, relaxed and not moving or speaking and the arm supported at the level of the heart ([@bibr38-1557988319825754]).

Biochemical Data {#section8-1557988319825754}
----------------

Some biochemical data (FBG \[mmol/L\]; TG \[mmol/L\]; TC \[mmol/L\]; HDL-C \[mmol/L\]; LDL-C \[mmol/L\]; uric acid \[µmol/L\]; creatinine \[µmol/L\]; urea \[mmol/L\]) were determined after a 12-hr period of fasting. FBG, TC, HDL-C, creatinine, and urea were quantified by spectrophotometry ([@bibr33-1557988319825754]). TG and uric acid were quantified by the colorimetric method. LDL-C was calculated ([@bibr21-1557988319825754]): LDL-C = TC − HDL-C − TG/5.

Applied Definitions {#section9-1557988319825754}
-------------------

Obesity status was categorized into normal weight (18.5 kg/m^2^ ≤ BMI ≤ 24.9 kg/m^2^), overweight (25.0 kg/m^2^ ≤ BMI ≤ 29.9 kg/m^2^), and obesity (BMI ≥ 30.0 kg/m^2^ \[[@bibr51-1557988319825754]\]). The MetS was retained in front of the presence of an android obesity (WC ≥ 94 cm \[[@bibr27-1557988319825754]; [@bibr54-1557988319825754]\]) plus any two of the following four factors ([@bibr27-1557988319825754]): raised TG (≥1.7 mmol/L); reduced HDL-C (\<1.03 mmol/L); raised SBP (≥130 mmHg) or DBP (≥85 mmHg); and raised FBG (≥5.6 mmol/L).

Statistical Analysis {#section10-1557988319825754}
--------------------

The Kolmogorov--Smirnov test was used to analyze variable distributions. Quantitative and qualitative data were expressed as means ± standard deviation (*SD*) (95% confidence interval \[CI\]) and as relative number (%), respectively. Mann--Whitney *U* and χ^2^ tests were used to compare quantitative data and percentages, respectively. Analyses were carried out using the Statistica statistical software (Statistica Kernel version 6; Stat Software. France). Significance was set at the .05 level.

Results {#section11-1557988319825754}
=======

Sixty-five voluntary participants were included. After applying the noninclusion criteria, only 58 were retained (29 ENSs and 29 AHNSs). The main reasons for noninclusion and/or exclusion were: DM (*n* = 4); antecedents of cerebral vascular stroke (*n* = 1); missing biochemical data (*n* = 1); and cumulated smoked narghile \>100 NY (*n* = 1).

[Table 1](#table1-1557988319825754){ref-type="table"} displays the characteristics of the participants. The most used tobacco type was *moassel* in almost three-quarter of ENSs. The two groups included similar percentages of males having high socioeconomic or schooling levels, or a normal weight or an overweight. Compared to the AHNSs' group, the ENSs' one was significantly older by \~4 years, and had significantly higher weight, BMI, and WC. The ENSs' group included significantly higher percentages of males having obesity or being regular alcoholic consumers.

###### 

Characteristics of the Two Groups of ENSs and AHNSs.

![](10.1177_1557988319825754-table1)

                                                      ENSs (*n* = 29)              AHNSs (*n* = 29)             *p*
  ----------------------------- --------------------- ---------------------------- ---------------------------- -------------------------------------------------------------
  Age                           (Years)               38 ± 5 (36 to 40)            34 ± 7 (31 to 36)            .018[\*](#table-fn2-1557988319825754){ref-type="table-fn"}
  Height                        \(m\)                 1.77 ± 0.08 (1.74 to 1.80)   1.76 ± 0.07 (1.73 to 1.78)   .272
  Weight                        (kg)                  89 ± 13 (84 to 94)           82 ± 10 (78 to 86)           .027[\*](#table-fn2-1557988319825754){ref-type="table-fn"}
  Waist circumference           \(cm\)                100 ± 10 (96 to 103)         95 ± 7 (92 to 98)            .007[\*](#table-fn2-1557988319825754){ref-type="table-fn"}
  Body mass index               (kg/m^2^)             28.2 ± 3.6 (26.9 to 29.6)    26.5 ± 2.6 (25.5 to 27.5)    .046[\*](#table-fn2-1557988319825754){ref-type="table-fn"}
  Obesity status                Normal weight         5 (17.2)                     9 (31.0)                     .22
                                Overweight            13 (44.8)                    18 (62.1)                    .17
                                Obesity               11 (37.9)                    2 (6.9)                      .04[\*](#table-fn2-1557988319825754){ref-type="table-fn"}
  Tobacco quantity              (Narghile-years)      18 ± 15 (12 to 24)           Not applied                  
  Tobacco type                  *Tombac*              0 (0.0)                      Not applied                  
                                *Jurak*               4 (13.8)                     Not applied                  
                                *Moassel*             21 (72.4)                    Not applied                  
                                *Jurak and Moassel*   4 (13.8)                     Not applied                  
  High schooling level                                27 (93.1)                    23 (79.3)                    .13
  High socioeconomic level                            25 (86.2)                    24 (82.7)                    .75
  Regular alcoholic consumers                         9 (31.0)                     1 (3.4)                      .006^[ᵻ](#table-fn2-1557988319825754){ref-type="table-fn"}^

*Note.* Quantitative data were mean ± SD (95% confidence interval). Qualitative data were number (%). ENSs = Exclusive Narghile Smokers; AHNSs = Apparently Healthy Nonsmokers; *p* = probability.

*p* \< .05 (Mann--Whitney *U* test): ENSs vs. AHNSs. ^ᵻ^*p* \< .05 (χ^2^ test): ENSs vs. AHNSs.

The two groups were matched with the family and personal medical and surgical histories ([Table 2](#table2-1557988319825754){ref-type="table"}).

###### 

Family and Personal Medical and Surgical Histories of the Two Groups of ENSs and AHNSs.

![](10.1177_1557988319825754-table2)

                                                                              ENSs (*n* = 29)   AHNSs (*n* = 29)   *p*
  ------------------------------------------------------- ------------------- ----------------- ------------------ ------
  Family history of:                                      Mellitus diabetes   15 (51.7)         19 (65.5)          .319
  Arterial hypertension                                   14 (48.3)           19 (65.5)         .197               
  Cerebral vascular stroke and/or myocardial infarction   7 (24.1)            6 (20.7)          .785               
  Dyslipidemia                                            11 (37.9)           10 (34.5)         .752               
  Thyroid dysfunction                                     4 (13.8)            7 (24.1)          .335               
  Surgical personal history of:                           Abdominal-pelvic    4 (13.8)          1 (3.4)            .147
  Urologic                                                2 (6.9)             0 (0.0)           .152               
  Orthopedic                                              4 (13.8)            3 (10.3)          .641               
  Neurological                                            1 (3.4)             0 (0.0)           .351               
  Others                                                  2 (6.9)             1 (3.4)           .487               

*Note.*Data were number (%). ENSs = Exclusive Narghile Smokers; AHNSs = Apparently Healthy Nonsmokers; *p* = probability.

*p* \< .05 (χ^2^ test): ENSs vs. AHNSs.

[Table 3](#table3-1557988319825754){ref-type="table"} displays the biochemical data of participants. The two groups had similar values of FBG, TC, HDL-C, LDL-C, urea, SBP, and DBP. Compared to the AHNSs' group, the ENSs' one had significantly higher values of TG and uric acid, but a significantly lower value of creatinine. The exclusion of alcohol consumers provided the same results ([Table 1S in the Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)) except for urea where AHNSs' (*n* = 28) values were significantly higher than those of ENSs (*n* = 21): 5.62 ± 1.36 versus 4.81 ± 1.05 mmol/L (*p* = .03).

###### 

Biochemical Data and Blood Pressure Values of the Two Groups of ENSs and AHNSs.

![](10.1177_1557988319825754-table3)

                                                    ENSs (*n* = 29)                     AHNSs (*n* = 29)                    *p*
  -------------------------------------- ---------- ----------------------------------- ----------------------------------- -------------------------------------------------------------
  Fasting glycaemia                      (mmol/L)   5.38 ± 0.58 (4.58 to 6.83)          5.60 ± 0.37 (4.82 to 6.41)          .060
  Triglycerides                          (mmol/L)   1.87 ± 0.85 (0.74 to 3.71)          1.22 ± 0.40 (0.55 to 2.11)          .001[\*](#table-fn6-1557988319825754){ref-type="table-fn"}
  Total cholesterol                      (mmol/L)   4.87 ± 1.16 (2.97 to 7.30)          4.36 ± 0.74 (3.01 to 5.62)          .076
  High-density lipoprotein cholesterol   (mmol/L)   0.92 ± 0.30 (0.50 to 2.05)          0.82 ± 0.21 (0.46 to 1.38)          .129
  Low-density lipoprotein cholesterol    (mmol/L)   3.09 ± 0.98 (1.70 to 5.3)0          2.92 ± 0.77 (1.46 to 4.34)          .594
  Uric acid                              (µmol/L)   324.43 ± 44.07 (235.00 to 438.00)   275.26 ± 62.27 (174.00 to 406.00)   .0009[\*](#table-fn6-1557988319825754){ref-type="table-fn"}
  Creatinine                             (µmol/L)   74.23 ± 12.53 (52.53 to 105.00)     90.46 ± 16.08 (59.00 to 125.00)     .0002[\*](#table-fn6-1557988319825754){ref-type="table-fn"}
  Urea                                   (mmol/L)   5.10 ± 1.28 (3.52 to 8.56)          5.64 ± 1.34 (3.41 to 8.53)          .076
  Systolic blood pressure                (mmHg)     117 ± 9 (100 to 150)                115 ± 8 (100 to 130)                .479
  Diastolic blood pressure               (mmHg)     76 ± 6 (60 to 80)                   73 ± 7 (60 to 80)                   .123

*Note.* Data were mean ± *SD* (95% confidence-interval). ENSs = Exclusive Narghile Smokers; AHNSs = Apparently Healthy Nonsmokers; *p =* probability.

*p* \< .05 (Mann--Whitney *U* test): ENSs vs. AHNSs.

[Table 4](#table4-1557988319825754){ref-type="table"} displays the participants' metabolic profiles. Compared to the AHNSs' group, the ENSs' group included similar percentages of males having android obesity, arterial hypertension, raised FBG, and MetS. The ENSs' group included a significantly lower percentage of males having low HDL-C and a significantly higher percentage of males having hypertriglyceridemia. The exclusion of alcohol consumers provided the same results ([Table 2S in the Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)) except for the frequencies of participants with a low HDL-C who were similar between the ENSs' and AHNSs' groups (65.0% vs. 82.1%; *p* = .187).

###### 

Metabolic Profiles of the Two Groups of ENSs and AHNSs.

![](10.1177_1557988319825754-table4)

                                                             ENSs (*n* = 29)   AHNSs (*n* = 29)   *p*
  ---------------------------------------------------------- ----------------- ------------------ --------------------------------------------------------------
  Android obesity                                            23 (79.3)         17 (59.6)          .08
  Systolic blood pressure ≥130 mmHg                          3 (10.3)          3 (10.3)           1.00
  Diastolic blood pressure ≥85 mmHg                          0 (0.0)           0 (0.0)            1.00
  Hypertension                                               3 (10.3)          3 (10.3)           1.00
  Fasting blood glycaemia ≥5.6 mmol/L                        11 (37.9)         14 (48.2)          .44
  Hypertriglyceridemia                                       15 (51.7)         3 (10.7)           \<.001[\*](#table-fn8-1557988319825754){ref-type="table-fn"}
  Low high-density lipoprotein cholesterol (\<1.03 mmol/L)   18 (62.0)         24 (82.7)          .04[\*](#table-fn8-1557988319825754){ref-type="table-fn"}
  Metabolic syndrome                                         15 (51.7)         10 (34.5)          .18

*Note.* Data were number (%). ENSs = Exclusive Narghile Smokers; AHNSs = Apparently Healthy Nonsmokers; *p =* probability.

*p* \< .05 (χ^2^ test): ENSs vs. AHNSs.

Discussion {#section12-1557988319825754}
==========

Two groups of 29 ENSs of more than five NY and 29 AHNSs were compared. On the one hand, the ENSs' group included a significantly lower percentage of males having low HDL-C (62.0% vs. 82.7%), but significantly higher percentages of males having obesity (37.9% vs. 6.9%) or hypertriglyceridemia (51.7% vs. 10.7%). On the other hand, the two groups of ENSs and AHNSs included similar percentages of males having normal weight (17.2% vs. 31.0%); overweight (44.8% vs. 62.1%); android obesity (79.3% vs. 59.6%), arterial hypertension (10.3% vs. 10.3%), raised FBG (37.9% vs. 48.2%), and MetS (51.7% vs. 34.5%). However, narghile use alters some biochemical data such as TG and uric acid: compared to the AHNSs' group, the ENSs' one had significantly higher values of TG (1.22 ± 0.40 vs. 1.87 ± 0.85 mmol/L) and uric acid (275.26 ± 62.27 vs. 324.43 ± 44.07 µmol/L). To the best of the authors' knowledge, this is the first specific comparative study exploring the adverse effects of narghile use on some biochemical data and metabolic profile. [Box 1](#table5-1557988319825754){ref-type="table"} highlights the novelty of this study compared to what is known in this area.

###### 

Highlights: Novelty of the present research compared to what is known in this area.

![](10.1177_1557988319825754-table5)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **WHAT IS KNOWN IN THIS AREA**

  • According the 2015 WHO advisory notes on narghile use, studies related to the epidemiology of narghile-associated disease risk are recommended.\
  • Studies about the effects of narghile use on biochemical data and metabolic profile are scarce and reported controversial conclusions.

  **NOVELTY OF THE PRESENT RESEARCH**

  • This study aimed to compare the biochemical data and the metabolic profile of ENSs (*n* = 29) with AHNSs (*n* = 29).\
  • Compared to the AHNSs' group, the ENSs' one had higher values of BMI, WC, and TG. The ENSs' group included a lower percentage of participants having low HDL-C, but higher percentages of participants having obesity or hypertriglyceridemia.\
  • ENSs' and AHNSs' groups had similar values of FBG, TC, HDL-C, LDL-C, and BP. The two groups included similar percentages of participants having normal weight; overweight; android obesity, hypertension, hyperglycemia, and metabolic syndrome.

  **IMPLICATIONS FOR FUTURE RESEARCH**

  There is a need to monitor narghile use among metabolic patients and include this information in their medical charts in the same manner cigarette consumption is documented.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For some years, narghile use has been considered as a global threat and has been given the status of an epidemic by public health officials ([@bibr4-1557988319825754]). The harmful effects of narghile use on smokers' biochemical data and metabolic profile highlighted in this study are part of a more general phenomenon ([@bibr7-1557988319825754]; [@bibr9-1557988319825754]; [@bibr13-1557988319825754]; [@bibr20-1557988319825754]; [@bibr31-1557988319825754]; [@bibr50-1557988319825754]). Although the harmful effects of cigarette consumption on health have been well documented, those of narghile use on biochemical data and/or metabolic profiles are less studied. A 2017 updated systematic review and meta-analysis ([@bibr50-1557988319825754]), including just one study ([@bibr43-1557988319825754]), reported that narghile use is likely to be associated with MetS (odds ratio \[OR\]: 1.63--1.95). Studies analyzing the biochemical data and the metabolic profile of ENSs are scarce, and to the finest of the authors' knowledge, only six have been published ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]). Their designs and the characteristics of included participants were exposed in [Table 3S (Appendix)](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754). The aforementioned studies had several methodological limitations and yielded conflicting results ([Tables 4S and 5S, Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). As specialists in the field of endocrinology and metabolic diseases are almost certain to encounter NSs amongst their patients, it is important to inform them of the significantly detrimental impacts of narghile use on smokers' biochemical data and how it can really lead to some metabolic problems.

Nosology {#section13-1557988319825754}
--------

Narghile is a sort of tobacco smoking. Charcoal heats tobacco which produces smoke that passes through water before being inhaled. Additional information about the different synonyms used to refer to narghile, the different names for the tobacco smoked during narghile use, and the different parts of a modern narghile are highlighted in the [Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754).

Discussion of the Methodology {#section14-1557988319825754}
-----------------------------

Discussion relative to the following points is highlighted in the [Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754): study design, sample size, applied medical questionnaire, narghile-use quantification, used tobacco, exposure level, number of examiners, and statistical analysis. Only the inclusion and the noninclusion criteria, the recruitment method, the comparison with control groups; the collected data, the applied definitions, and the study limitations will be discussed.

The noninclusion criteria varied between relative studies ([Table 3S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). This makes the comparison between their data difficult. Since the prevalence of MetS is sex dependent ([@bibr41-1557988319825754]) and increases with age ([@bibr40-1557988319825754]) and since some biochemical data are directly associated with sex (e.g., males experienced greater FBG levels than females \[[@bibr36-1557988319825754]\]), only males aged 20--45 years were included. In relative studies, age varied between 18 years ([@bibr26-1557988319825754]) and 75 years ([@bibr43-1557988319825754]), and in some, both sexes were included ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr36-1557988319825754]; [@bibr43-1557988319825754]; [Table 3S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). All similar studies reported the "exclusive" character of the narghile use ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]). This is a strong point, because ignoring the profile of volunteers participating in the experiment is a methodological error ([@bibr11-1557988319825754]). The body keeps a memory of the smokers' physiological and behavioral practices ([@bibr12-1557988319825754]). For this reason, only ENSs should be evaluated in the group of NSs. Some important noninclusion criteria (e.g., known history of metabolic and/or CVDs and any specific treatment for lipid abnormality) known to modify the biochemical data were applied in order to avoid any confusion. In this study, the type of narghile tobacco (*moassel* and/or *jurak*) was identified. This important information, neglected in some studies ([@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]), makes comparisons complicated because in case of other used narghile tobacco (such as *tombak* frequently used in Saudi Arabia) in comparison to *tabamel*, the pattern is different ([@bibr6-1557988319825754]). It is established that socioeconomic and/or schooling levels impact the prevalence of MetS with higher education and/or income associated with lower prevalence ([@bibr32-1557988319825754]). In the study of [@bibr43-1557988319825754], the socioeconomic levels of the ENSs and HNSs were different ([Tables 3S and 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). In this study, the two groups were matched with the socioeconomic and schooling levels. The two groups higher percentages of participants with high socioeconomic and schooling levels ([Table 1](#table1-1557988319825754){ref-type="table"}) reflected the "real life" as previously seen in a local study aiming at evaluating the smokers' handicap status ([@bibr5-1557988319825754]) or in a Libyan study ([@bibr45-1557988319825754]) where 75.2% and 86.6% of ENSs were, respectively, having education up to secondary school or college and of high income group. The higher frequencies of android obesity (59.6%) and MetS (34.5%) observed in the AHNSs' group also reflect the "real life" of Tunisian male adults ([@bibr23-1557988319825754]). In a sample of 393 adults aged 18--75 years and randomly recruited from the general population, the prevalences of android obesity and MetS were respectively, 47.1% and 38.5% ([@bibr23-1557988319825754]). As done in some studies, ENSs were recruited via flyers distributed in the local city cafés ([@bibr2-1557988319825754]) and AHNSs from acquaintances of people involved in this study ([@bibr36-1557988319825754]; [@bibr43-1557988319825754]). Other recruitment methods, highlighted in [Table 3S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754), were reported. In this study, and as done in some relative ones ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [Table 3S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)), participants were selected by a convenience sampling. Similarly to any study using this recruitment method for its relative ease of access to volunteers, availability and the quickness with which data can be gathered, there was a possibility of volunteer bias ([@bibr22-1557988319825754]). The inclusion of volunteers during clinical studies leads to a selection bias because researchers may unconsciously approach some kinds of respondents and avoid others, and so the sample might not represent the population as a whole ([@bibr35-1557988319825754]).

As previously carried out by some authors ([@bibr2-1557988319825754]; [@bibr26-1557988319825754]; [@bibr34-1557988319825754]; [@bibr36-1557988319825754]; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]), a control group of AHNSs was included. In some relative studies, additional control groups of ECSs and/or mixed smokers (MSs) of narghile and cigarettes, and ex-ECSs were included ([Table 3S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). Taking four groups of HNSs, ENSs, ECSs and MSs (as done by [@bibr42-1557988319825754]) or three groups of HNSs, ENSs and ECSs (as done by [@bibr26-1557988319825754]) into a single study seems to have little precedent in the literature and raises some questions, such as whether the prevalence of some epidemiological data (e.g., schooling and socioeconomic levels) in those groups was comparable.

As it was carried out in some relative studies ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)), the following anthropometric and fasting blood biochemical data were noted/collected: BMI, WC, SBP, DBP, FBG, TG, TC, HDL-C, LDL-C, uric acid, creatinine, urea. Some additional biochemical data were presented as ratios: HDL-C/LDL-C, HDL-C/TG, and TC/HDL-C ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). As performed in scarce relative studies ([Tables 4S and 5S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)), the following entities have been also investigated: obesity status, android obesity, low HDL-C, hypertriglyceridemia, hyperglycemia, hypertension, and MetS. As done by [@bibr42-1557988319825754], it was better to add an additional entity, such as dyslipidemia ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). In this study, the MetS was the main outcome used to evaluate the metabolic profile and to calculate the sample size. As done by some authors ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]), the MetS was defined according to the [@bibr27-1557988319825754] consensus ([@bibr27-1557988319825754]). Compared to this study's MetS criteria, the aforementioned two ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]) had two main differences. These differences concern the applied WC threshold (e.g., for males: 94 vs. 90; [@bibr42-1557988319825754]; [@bibr43-1557988319825754]) and the consideration of specific treatments for lipid abnormality, and/or hypertension and/or MD ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]). In this study, the applied definitions for low HDL-C, hypertriglyceridemia, hyperglycemia, and hypertension were similar to these retained by [@bibr43-1557988319825754].

This study presents three limitations. The major one was the lack of evaluation of the diet regimen and physical activity status of the participants. As highlighted by [@bibr43-1557988319825754], differential dietary intake and physical activity may have confounded the apparent relationship between narghile use and MetS and/or biochemical data. On the one hand, one meta-analysis concluded that low glycemic index diets reduce TC and LDL-C but have no effect on HDL-C or TG ([@bibr24-1557988319825754]), and another study identified that a vegetarian diet was associated with lower HDL-C concentrations ([@bibr29-1557988319825754]). On the other hand, "light" and "moderate-to-vigorous" physical activities had a differential effect on risk markers of cardio-metabolic health ([@bibr17-1557988319825754]). One meta-analysis indicated that dietary and/or physical activity interventions for MetS reduce android obesity with no adverse effects ([@bibr17-1557988319825754]). BMI was evaluated as another proxy measure of dietary intake and physical activity. As compared to the AHNSs' group, the ENSs' one had a higher BMI and included a higher percentage of obese males ([Table 1](#table1-1557988319825754){ref-type="table"}), so we can hypothesize that the two groups had different diet regimens and physical activity status. Given that narghile is smoked in gatherings with people sitting around, exposure to second-hand smoke may have some influence on this study's results. Some of the AHNSs may have been exposed to second-hand smoke through contaminated air and this resulted in an impairment in their metabolic profile as well. If this was true, it is unlikely to affect the observed relationship of narghile use and MetS. However, the harmful effects of narghile use observed in this study may have been attenuated and true effect may even be stronger than the observed effect. The last limitation concerns the inclusion of a higher percentage of ENSs who were regular alcohol consumers ([Table 1](#table1-1557988319825754){ref-type="table"}). This could be a source of confusion and could influence some reported biochemical data ([@bibr16-1557988319825754]; [@bibr19-1557988319825754]). In fact, biochemical abnormalities (e.g., hypoglycemia, high HDL-C) are common among chronic alcoholics ([@bibr16-1557988319825754]; [@bibr19-1557988319825754]). However, according to the literature, it seems that among lifetime NSs, 17% ([@bibr28-1557988319825754]) to 28.6% ([@bibr15-1557988319825754]) were lifetime alcoholics. Moreover, [@bibr26-1557988319825754] reported that 73.3% of current CSs who were current NSs were alcohol consumers. Consequently, it seems that this study ENSs' group reflected the "real life" of NSs as seen in practice. Moreover, a recent meta-analysis suggested that heavy alcohol consumption might be associated with an increased risk of MetS while very light alcohol consumption seemed to be associated with a reduced risk of MetS ([@bibr46-1557988319825754]).

Discussion of Results {#section15-1557988319825754}
---------------------

Compared to the AHNSs' group, the ENSs' one had significantly higher weight, BMI, WC, TG, and uric acid, but a significantly lower value of creatinine. The ENSs' group included a significantly lower percentage of males having low HDL-C; nevertheless, significantly higher percentages of males having obesity or hypertriglyceridemia. Conversely, the two groups included similar percentages of males having normal weight; overweight; android obesity, arterial hypertension, raised FBG, and MetS. Moreover, the latter were matched with FBG, TC, HDL-C, LDL-C, urea, and SBP and DBP values.

### Effects on anthropometric data and obesity status {#section16-1557988319825754}

This study's findings concerning weight, BMI, and WC ([Table 1](#table1-1557988319825754){ref-type="table"}) are intermediate between these reported in two similar ones ([@bibr34-1557988319825754]; [@bibr43-1557988319825754]; [Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). On the one hand, and contrary to this study's findings, [@bibr34-1557988319825754] reported that the three groups of ENSs, ECSs, and HNSs were matched with weight and BMI. On the other hand, and as noted in this study, [@bibr43-1557988319825754] reported that compared to the HNSs' group, the ENSs' group had a significantly higher WC (81 ± 12 vs. 85 ± 13 cm). A recent population-based study aiming at evaluating the relationship between narghile use and weight, concluded that daily NSs, compared to HNSs, had higher BMI, translating into 6 extra kilograms of weight on average ([@bibr49-1557988319825754]).

Compared to the AHNS' group, the ENS' group included a higher percentage of obese males ([Table 1](#table1-1557988319825754){ref-type="table"}). This result is in line with that reported by [@bibr42-1557988319825754] who noted a positive association between narghile use and obesity, which was not established in case of cigarette consumption ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). This obesity can be related to the sedentary life style opted by ENSs ([@bibr5-1557988319825754]; [@bibr8-1557988319825754]).

### Effects on blood pressures data {#section17-1557988319825754}

The finding of this study concerning blood pressures ([Table 3](#table3-1557988319825754){ref-type="table"}) is opposite to that reported by [@bibr43-1557988319825754] who noted significantly higher SBP and DBP values in ENSs compared to HNSs (130 ± 22 vs. 124 ± 20 mmHg and 74 ± 10 vs. 72 ± 10 mmHg, respectively). A previous local study aiming at evaluating the deficiency and incapacity of ENSs compared to HNSs identified a significant difference between their DBP (85 ± 10 vs. 78 ± 16 mmHg), nevertheless their SBP were similar (132 ± 13 vs. 129 ± 18 mmHg; [@bibr8-1557988319825754]). A recent systematic review highlighted that narghile use was associated with an increase in blood pressure ([@bibr25-1557988319825754]).

### Effects on blood lipid data {#section18-1557988319825754}

Lipid data are an integral part of the search for the factors of cardiovascular risk. The two groups of ENSs and AHNSs were matched with TC, HDL-C, and LDL-C. Compared to the AHNSs' group, the ENSs' group had significantly higher TG values ([Table 3](#table3-1557988319825754){ref-type="table"}). The effects of narghile use on the aforementioned data are controversial ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)).

Similar to this study's findings, some authors reported that compared to the HNSs' group, the ENSs' group had significantly higher TG values (1.6 ± 1.0 vs. 1.4 ± 0.90 mmol/L \[[@bibr43-1557988319825754]\]; 1.38 ± 0.32 vs. 0.9 ± 0.02 mmol/L \[[@bibr34-1557988319825754]\]). In some other studies, no statistical difference between TG values of ENSs as compared to HNSs ([@bibr2-1557988319825754]; [@bibr42-1557988319825754]), to ECSs ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr42-1557988319825754]), to MSs ([@bibr42-1557988319825754]), and to ex-ECS ([@bibr42-1557988319825754]) was found.

Similar to this study's findings, no statistical difference between TC values of ENSs as compared to HNSs was identified in a Tunisian study ([@bibr34-1557988319825754]). Comparison of ENSs TC values with these of ex-ECSs ([@bibr42-1557988319825754]) or MSs ([@bibr42-1557988319825754]) reported similar data. [@bibr42-1557988319825754] reported that compared to the HNSs' group, the ENSs one had significantly lower TC values (4.93 ± 0.97 vs. 4.97 ± 1.02 mmol/L). Comparisons of TC values between ENSs and ECSs are also controversial. While [@bibr42-1557988319825754] identified similar data between the two groups, [@bibr34-1557988319825754] reported that compared to the ECSs' group, the ENSs' group had significantly lower TC values (4.36 ± 0.11 vs. 4.48 ± 0.09 mmol/L).

Akin to the results of this study, no statistical difference between HDL-C values of ENSs compared to HNSs was reported in two studies ([@bibr2-1557988319825754]; [@bibr43-1557988319825754]). Comparisons of ENSs HDL-C values with those of ECSs ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr42-1557988319825754]), ex-ECSs ([@bibr42-1557988319825754]), or MSs ([@bibr42-1557988319825754]) identified similar data. Compared to the HNSs' group, the ENSs' group had significantly lower HDL-C values (1.12 ± 0.12 vs. 0.97 ± 0.05 mmol/L \[[@bibr34-1557988319825754]\]; 1.12 ± 0.26 vs. 1.09 ± 0.23 mmol/L).

In accordance with this study's findings, no statistical difference between LDL-C values of ENSs compared to HNSs was identified in two studies ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]). Comparisons of ENSs LDL-C values with these of ECSs ([@bibr2-1557988319825754]; [@bibr34-1557988319825754]; [@bibr42-1557988319825754]), ex-ECSs ([@bibr42-1557988319825754]) or MSs ([@bibr42-1557988319825754]) reported comparable data. One study ([@bibr42-1557988319825754]) established that compared to the HNSs' group, the ENSs' group had significantly higher LDL-C values (3.01 ± 0.92 vs. 3.03 ± 0.97 mmol/L). It is important to highlight that the LDL-C mean value of ENSs reported by [@bibr26-1557988319825754] (4.24 ± 0.65 mmol/L) was the highest one among all relative studies ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). [@bibr26-1557988319825754] highlighted two additional results: (a) The LDL-C of ENSs correlated with SBP, DBP, TC, and BMI, but did not correlate with WC, heart rate, HDL-C, TG, and FBG. (b) Among the current CSs who were current NSs, a significant increase in LDL-c level was observed relative to current CSs who were not NSs.

### Effects on FBG {#section19-1557988319825754}

The effects of narghile use on FBG are controversial ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). Akin to this study's findings, some authors ([@bibr36-1557988319825754]; [@bibr42-1557988319825754]) identified no difference between FBG values of ENSs as compared to HNSs ([@bibr36-1557988319825754]; [@bibr42-1557988319825754]), ex-ECSs ([@bibr42-1557988319825754]), or MSs ([@bibr42-1557988319825754]). In other studies ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]), FBG mean values were significantly higher in ENSs as compared to HNSs (5.2 ± 1.7 vs. 4.9 ± 1.2 mmol/L; [@bibr43-1557988319825754]) or to ECSs (5.14 ± 2.33 vs. 4.86 ± 1.88 mmol/L; [@bibr42-1557988319825754]).

### Effects on uric acid, urea, and creatinine data {#section20-1557988319825754}

Only one related study ([@bibr42-1557988319825754]) evaluated the abovementioned data. Contrary to this study's results, where compared to the AHNSs' group, the ENSs' group had a significantly higher uric acid mean value ([Table 3](#table3-1557988319825754){ref-type="table"}), [@bibr42-1557988319825754] reported that the two groups were matched for this data ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). The authors indicated that compared to the ECSs' group, the ENSs' one had lower uric acid values (274.82 ± 83.28 vs. 259.33 ± 78.51 µmol/L; [@bibr42-1557988319825754]). Contrarily to these study results, where compared to the AHNSs' group, the ENSs' one had a significantly lower creatinine mean value ([Table 3](#table3-1557988319825754){ref-type="table"}), [@bibr42-1557988319825754] revealed that the two groups matched this data ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). The authors reported no significant difference between ENSs and ECSs or ex-ECSs or MSs. Similarly, to this study findings ([Table 3](#table3-1557988319825754){ref-type="table"}), [@bibr42-1557988319825754] indicated that the ENSs' and ECSs' groups were matched with the urea values ([Table 4S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)).

### Effects on metabolic profile {#section21-1557988319825754}

Only one previous study ([@bibr43-1557988319825754]) evaluated the metabolic profile of ENSs and HNSs ([Table 5S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). The authors ([@bibr43-1557988319825754]) noted that compared to HNSs, ENSs were significantly more likely to have hypertriglyceridemia (OR: 1.60), hyperglycemia (OR: 1.88), hypertension (OR: 1.31), and android obesity (OR: 1.21). In a Libyan cross-sectional study including 242 regular ENSs, prevalences of hypertension, DM, and ischemic heart disease were 44.5%, 33.9%, and 8.5%, respectively ([@bibr45-1557988319825754]). The aforementioned reported health problems were significantly higher among NSs aged 35 years and more, with a narghile duration-use higher than 20 years, and who smoked more than thrice a week ([@bibr45-1557988319825754]).

The unexpected lower percentage of ENSs having low HDL-C (62.0%) compared to that observed in AHNSs (82.7%) can be explained by the higher frequency of alcohol consumers included in the ENSs group ([Table 1](#table1-1557988319825754){ref-type="table"}; [@bibr14-1557988319825754]; [@bibr16-1557988319825754]). Indeed, the exclusion of alcohol consumers provided comparable percentages between the two groups ([Table 2S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). In fact, it was previously identified that alcohol consumption increases HDL-C in a dose-dependent fashion, associated with and possibly caused by, an increase in the transport rate of HDL apolipoproteins apoA-I and --II ([@bibr16-1557988319825754]).

Smoking has been consistently linked with CVD; recent evidence suggests that MetS is the potential link between tobacco smoking and CVDs ([@bibr18-1557988319825754]). MetS is a cluster of risk factors which have revealed a strong relationship with the risk of CVDs. Individuals with MetS are twice as likely to die from CVDs, and three times more likely to have a heart attack/stroke compared with people without MetS ([@bibr27-1557988319825754]). The unexpected result concerning the frequencies of MetS ([Table 4](#table4-1557988319825754){ref-type="table"}) is contrary to that observed in two previous studies ([@bibr42-1557988319825754]; [@bibr43-1557988319825754]; [Table 5S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)). On the one hand, [@bibr43-1557988319825754] reported that age adjusted-prevalence of MetS was significantly higher among ENSs (33.1%) compared with HNSs (14.8%). ENSs were three times more likely to have MetS compared with HNSs after adjustment of age, sex, and social class ([@bibr43-1557988319825754]). [@bibr42-1557988319825754] noted a positive association between narghile use and MetS, which was not established in cigarette consumption. Prevalence of MetS was significantly higher in ENSs (46.8%) in comparison with HNSs (38.8%). The higher percentage of ENSs who were lighter alcohol consumers can be advanced to explain the lack of a significant difference between the two groups concerning the frequency of MetS, since very light alcohol consumption seemed to be associated with a reduced risk of MetS ([@bibr46-1557988319825754]). The above hypothesis cannot be retained since a similar result was observed after exclusion of alcohol consumers ([Table 2S](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754)).

Other interesting results, relative to percentages of participants with CVDs, or DM, or dyslipidemia, were observed by [@bibr42-1557988319825754]. The authors stated that after adjustment of age and sex, the presence of CVDs (12.9%, 13.6%, 19.0%, 10.0%, and 12.3%, respectively, in NSs, current-CSs, ex-CSs, MSs, and HNSs), DM (17.1%, 9.8%, 18.9%, 16.2%, and 14.0%, respectively in NSs, current-CSs, ex-CSs, MSs, and HNSs), and dyslipidemia (67.1%, 75.1%, 70.9%, 80.5%, and 65.5%, respectively in NSs, current-CSs, ex-CSs, MSs, and HNSs) was significantly related to the smoking status. Moreover, dyslipidemia was associated with narghile use. In a Lebanon study performed on patients undergoing cardiac catheterization, [@bibr39-1557988319825754] noted that MI was significantly and independently associated with narghile use (OR: 1.33), which is lower than that for cigarette consumption (OR:1.87). Moreover, only DM presented significant association with narghile use among MI enrollees (OR: 1.66).

### Underlying mechanisms of narghile use {#section22-1557988319825754}

These study findings are biologically plausible in many ways related to the harmful effects of the narghile smoke compounds. The biological mechanisms responsible for the effects of narghile use on smokers' biochemical data are not elusive. Some mechanisms, related to the effects of some deleterious gases included in the narghile smoke, are advanced and detailed in the [Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988319825754).

Public Health Implications {#section23-1557988319825754}
==========================

Health education and awareness are perhaps the most crucial interventions required to be delivered for NSs, so that the false perceptions about the narghile-use harmlessness can be changed and its adverse effects could be assessed by the community. There is a need to monitor narghile use among metabolic patients and include this information in their medical charts in the same manner that cigarette consumption is documented. This is likely to increase awareness of the hazards of narghile use and prompt physicians to target narghile tobacco control by providing their patients with advice about narghile-use cessation.

In conclusion, narghile use alters some metabolic data (e.g., TG, uric acid, and creatinine) and some constituents of MetS (e.g., hypertriglyceridemia). Thus, global actions against this type of smoking are necessary.

Supplemental Material {#section24-1557988319825754}
=====================
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